Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China.
<h4>Background</h4>Anti-tuberculosis drug induced liver injury (ATLI) is emerging as a significant threat to tuberculosis control in China, though limited data is available about the burden of ATLI at population level. This study aimed to estimate the incidence of ATLI, to better underst...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2011
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/83a444dda8f54a5ebff90cae7b14de65 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:83a444dda8f54a5ebff90cae7b14de65 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:83a444dda8f54a5ebff90cae7b14de652021-11-18T06:50:44ZIncidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China.1932-620310.1371/journal.pone.0021836https://doaj.org/article/83a444dda8f54a5ebff90cae7b14de652011-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21750735/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>Anti-tuberculosis drug induced liver injury (ATLI) is emerging as a significant threat to tuberculosis control in China, though limited data is available about the burden of ATLI at population level. This study aimed to estimate the incidence of ATLI, to better understand its clinical features, and to evaluate its impact on anti-tuberculosis (TB) treatment in China.<h4>Methodology/principal findings</h4>In a population-based prospective study, we monitored 4,304 TB patients receiving directly observed treatment strategy (DOTS) treatment, and found that 106 patients developed ATLI with a cumulative incidence of 2.55% (95% Confidence Interval [CI], 2.04%-3.06%). Nausea, vomiting and anorexia were the top three most frequently observed symptoms. There were 35 (33.02%) ATLI patients with no symptoms, including 8 with severe hepatotoxicity. Regarding the prognosis of ATLI, 84 cases (79.25%) recovered, 18 (16.98%) improved, 2 (1.89%) failed to respond to the treatment with continued elevation of serum alanine aminotransferase, and 2 (1.89%) died as result of ATLI. Of all the ATLI cases, 74 (69.81%) cases changed their anti-TB treatment, including 4 (3.77%) cases with medication administration change, 21 (19.81%) cases with drugs replacement, 54 (50.94%) cases with therapy interruption, and 12 (11.32%) cases who discontinued therapy. In terms of treatment outcomes, 53 (51.46%) cases had TB cured in time, 48 (46.60%) cases had therapy prolonged, and 2 (1.94%) cases died. Compared with non-ATLI patients, ATLI patients had a 9.25-fold (95%CI, 5.69-15.05) risk of unsuccessful anti-TB treatment outcomes and a 2.11-fold (95%CI, 1.23-3.60) risk of prolonged intensive treatment phase.<h4>Conclusions/significance</h4>ATLI could considerably impact the outcomes of anti-TB treatment. Given the incidence of ATLI and the size of TB population in China, the negative impact is substantial. Therefore, more research and efforts are warranted in order to enhance the diagnosis and the prevention of ATLI.Penghui ShangYinyin XiaFeiying LiuXiaomeng WangYanli YuanDaiyu HuDehua TuYixin ChenPeiyuan DengShiming ChengLin ZhouYu MaLizhen ZhuWeiwei GaoHongyuan WangDafang ChenLi YangPingping HeShanshan WuShaowen TangXiaozhen LvZheng ShuYuan ZhangZhirong YangYan ChenNa LiFeng SunFeng SunXiaoting LiYingjian HePaul GarnerSiyan ZhanPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 6, Iss 7, p e21836 (2011) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Penghui Shang Yinyin Xia Feiying Liu Xiaomeng Wang Yanli Yuan Daiyu Hu Dehua Tu Yixin Chen Peiyuan Deng Shiming Cheng Lin Zhou Yu Ma Lizhen Zhu Weiwei Gao Hongyuan Wang Dafang Chen Li Yang Pingping He Shanshan Wu Shaowen Tang Xiaozhen Lv Zheng Shu Yuan Zhang Zhirong Yang Yan Chen Na Li Feng Sun Feng Sun Xiaoting Li Yingjian He Paul Garner Siyan Zhan Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China. |
| description |
<h4>Background</h4>Anti-tuberculosis drug induced liver injury (ATLI) is emerging as a significant threat to tuberculosis control in China, though limited data is available about the burden of ATLI at population level. This study aimed to estimate the incidence of ATLI, to better understand its clinical features, and to evaluate its impact on anti-tuberculosis (TB) treatment in China.<h4>Methodology/principal findings</h4>In a population-based prospective study, we monitored 4,304 TB patients receiving directly observed treatment strategy (DOTS) treatment, and found that 106 patients developed ATLI with a cumulative incidence of 2.55% (95% Confidence Interval [CI], 2.04%-3.06%). Nausea, vomiting and anorexia were the top three most frequently observed symptoms. There were 35 (33.02%) ATLI patients with no symptoms, including 8 with severe hepatotoxicity. Regarding the prognosis of ATLI, 84 cases (79.25%) recovered, 18 (16.98%) improved, 2 (1.89%) failed to respond to the treatment with continued elevation of serum alanine aminotransferase, and 2 (1.89%) died as result of ATLI. Of all the ATLI cases, 74 (69.81%) cases changed their anti-TB treatment, including 4 (3.77%) cases with medication administration change, 21 (19.81%) cases with drugs replacement, 54 (50.94%) cases with therapy interruption, and 12 (11.32%) cases who discontinued therapy. In terms of treatment outcomes, 53 (51.46%) cases had TB cured in time, 48 (46.60%) cases had therapy prolonged, and 2 (1.94%) cases died. Compared with non-ATLI patients, ATLI patients had a 9.25-fold (95%CI, 5.69-15.05) risk of unsuccessful anti-TB treatment outcomes and a 2.11-fold (95%CI, 1.23-3.60) risk of prolonged intensive treatment phase.<h4>Conclusions/significance</h4>ATLI could considerably impact the outcomes of anti-TB treatment. Given the incidence of ATLI and the size of TB population in China, the negative impact is substantial. Therefore, more research and efforts are warranted in order to enhance the diagnosis and the prevention of ATLI. |
| format |
article |
| author |
Penghui Shang Yinyin Xia Feiying Liu Xiaomeng Wang Yanli Yuan Daiyu Hu Dehua Tu Yixin Chen Peiyuan Deng Shiming Cheng Lin Zhou Yu Ma Lizhen Zhu Weiwei Gao Hongyuan Wang Dafang Chen Li Yang Pingping He Shanshan Wu Shaowen Tang Xiaozhen Lv Zheng Shu Yuan Zhang Zhirong Yang Yan Chen Na Li Feng Sun Feng Sun Xiaoting Li Yingjian He Paul Garner Siyan Zhan |
| author_facet |
Penghui Shang Yinyin Xia Feiying Liu Xiaomeng Wang Yanli Yuan Daiyu Hu Dehua Tu Yixin Chen Peiyuan Deng Shiming Cheng Lin Zhou Yu Ma Lizhen Zhu Weiwei Gao Hongyuan Wang Dafang Chen Li Yang Pingping He Shanshan Wu Shaowen Tang Xiaozhen Lv Zheng Shu Yuan Zhang Zhirong Yang Yan Chen Na Li Feng Sun Feng Sun Xiaoting Li Yingjian He Paul Garner Siyan Zhan |
| author_sort |
Penghui Shang |
| title |
Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China. |
| title_short |
Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China. |
| title_full |
Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China. |
| title_fullStr |
Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China. |
| title_full_unstemmed |
Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China. |
| title_sort |
incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (atli) in china. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2011 |
| url |
https://doaj.org/article/83a444dda8f54a5ebff90cae7b14de65 |
| work_keys_str_mv |
AT penghuishang incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT yinyinxia incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT feiyingliu incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT xiaomengwang incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT yanliyuan incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT daiyuhu incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT dehuatu incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT yixinchen incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT peiyuandeng incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT shimingcheng incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT linzhou incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT yuma incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT lizhenzhu incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT weiweigao incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT hongyuanwang incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT dafangchen incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT liyang incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT pingpinghe incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT shanshanwu incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT shaowentang incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT xiaozhenlv incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT zhengshu incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT yuanzhang incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT zhirongyang incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT yanchen incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT nali incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT fengsun incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT fengsun incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT xiaotingli incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT yingjianhe incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT paulgarner incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT siyanzhan incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina |
| _version_ |
1718424303687434240 |